Interpace Biosciences Announces New PLA Code and Medicare Reimbursement Increase for Proprietary Thyroid Assay, ThyGeNEXT®
05 avr. 2021 16h05 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that Novitas, its Medicare Administrative Contractor, has...
Interpace Biosciences Announces License Agreement with Rutgers University and Mass General Hospital
01 févr. 2021 09h27 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) announced today that it has executed a license agreement with Rutgers, The State University of New...
Interpace Biosciences Receives Nasdaq Deficiency Notice Due to Delayed Filing of Form 10-Q; No Immediate Impact on Listing
19 nov. 2020 16h11 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (NASDAQ: IDXG) on November 18, 2020 received notice from the Listing Qualifications Staff...
Interpace Biosciences Announces Results of Seminal Clinical Validation Study for Thyroid Assays
26 oct. 2020 06h30 HE
|
Interpace Biosciences, Inc.
Study Demonstrates Superior Performance of ThyGeNEXT® and ThyraMIR® vs. Other Molecular Tests PARSIPPANY, NJ, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG)...
Interpace Biosciences Announces Second Quarter 2020 Financial and Business Results
20 oct. 2020 08h00 HE
|
Interpace Biosciences, Inc.
Year to Date Net Revenue of $14.6 Million Up 19% vs Prior Year; Second Quarter Net Revenue of $5.4 Million Publication of Seminal Clinical Validation Study Related to Thyroid Products ...
Interpace Announces Acceptance of Seminal Clinical Validation Study for Thyroid Assays
21 juil. 2020 06h05 HE
|
Interpace Biosciences, Inc.
Podium Presentation Accepted for the American Society of Cytopathology (ASC) Annual Meeting PARSIPPANY, NJ, July 21, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG)...
Interpace Biosciences Announces Full Year and Fourth Quarter 2019 Financial and Business Results and Preliminary Q1-2020 Results
22 avr. 2020 16h05 HE
|
Interpace Biosciences, Inc.
Acquired Biopharma Business of Cancer Genetics in Second Half of 2019 Through Q1-2020 Raised $47 million from Two Top Private Equity FirmsProvides First Quarter 2020 Range of Revenues Expects to...
Interpace Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter, Full Year 2019 and Preliminary First Quarter 2020 Financial Results on Wednesday, April 22, 2020
22 avr. 2020 13h38 HE
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, April 22, 2020 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will release its financial results for the fourth quarter and full year 2019 this afternoon. Company...
Interpace Diagnostics Announces Contract with BCBS of Massachusetts
10 mars 2020 06h55 HE
|
Interpace Biosciences, Inc.
In-Network Access for More Than 3 Million Members Parsippany, NJ, March 10, 2020 (GLOBE NEWSWIRE) -- Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced...
Interpace Biosciences Announces Acceptance of first paper Demonstrating Clinical Performance of ThyGeNEXT with ThyraMIR
02 mars 2020 06h55 HE
|
Interpace Biosciences, Inc.
Parsippany, NJ, March 02, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced acceptance of the first manuscript reporting the clinical performance of the company’s...